サマリー

世界の末梢神経障害治療市場 2023-2027
Technavioは、末梢神経障害治療市場を監視しており、2023年から2027年にかけて3億7256万ドルの成長が見込まれ、予測期間中にCAGR 3.81%で加速しています。当レポートでは、末梢神経障害治療市場の全体分析、市場規模と予測、動向、成長促進要因、課題に加え、約25社のベンダーを網羅したベンダー分析を行っています。
現在の世界市場のシナリオ、最新動向とドライバー、市場全体の環境に関する最新の分析を提供しています。市場は、末梢神経障害の有病率の増加、末梢神経障害に対する最近の医薬品承認、末梢神経障害に対する認知度の向上が原動力となっています。
Technavioの末梢神経障害治療市場は、以下のように区分されています。
タイプ別
- 糖尿病性末梢神経障害
- 糖尿病性末梢神経障害 化学療法による末梢神経障害
- その他
地域別状況
- 北アメリカ
- 欧州
- アジア
- その他の地域 (ROW)
本調査では、今後数年間における末梢神経障害治療市場の成長を促進する主な理由の一つとして、強力な医薬品パイプラインを挙げています。また、新しい製剤による技術の進歩やジェネリック医薬品の普及が、市場の大きな需要につながると考えられます。
Technavio社は、主要パラメータの分析を通じて、複数の情報源からのデータの調査、合成、集計を行い、市場の詳細な姿を提示します。末梢神経障害治療市場に関する当レポートの対象領域は以下の通りです。
- 末梢神経障害治療市場のサイジング
- 末梢性神経障害治療市場予測
- 末梢神経障害治療市場の産業分析
Technavioの強力なベンダー分析は、お客様が市場での地位を向上できるように設計されており、これに沿って本レポートでは、Apotex Inc.、Assertio Therapeutics Inc、AstraZeneca Plc、Cadila Pharmaceuticals Ltd、Cipla Ltd、第一三共 Co., Ltd.など、いくつかの主要末梢神経障害治療市場ベンダーに関する詳細分析を掲載しています。アストラゼネカ社、カディラ社、シプラ社、第一三共社、ドクター・レディス・ラボラトリーズ社、イーライリリー社、エンド・インターナショナル社、グリュンエンタール社、ヒグマ社、ジョンソン＆ジョンソン社、ルパン社、ノバルティス社、ファイザー社、シオノギ・アンド・カンパニー社、サン・ファーマシューティカル・インダストリーズ社、エーザイ社、エーザイ・ノースアメリカ社、エーザイ・ノースアメリカ社Ltd.、Sun Pharmaceutical Industries Ltd.、Teva Pharmaceutical Industries Ltd.、UCB SA、およびViatris Inc.が含まれます。また、末梢神経障害治療市場の分析レポートには、今後の動向や市場成長に影響を与える課題に関する情報も含まれています。これは、企業が今後訪れるすべての成長機会を戦略的に活用するのに役立つものです。
本調査は、業界の主要参加者からのインプットを含め、一次情報と二次情報の客観的な組み合わせを使用して実施しました。本レポートには、主要ベンダーの分析に加え、包括的な市場およびベンダーランドスケープが含まれています。本レポートの詳細については、https://www.technavio.com/report/peripheral-neuropathy-treatment-market-industry-analysis をご覧ください。
Technavio社は、利益、価格、競争、プロモーションなどの主要パラメータの分析を通じて、複数のソースからのデータの調査、合成、総括を行い、市場の詳細な姿を提示します。業界の主要な影響力を持つ人物を特定することで、様々な市場の様相を提示しています。提示されるデータは、包括的で信頼性が高く、一次および二次にわたる広範な調査の結果である。Technavioの市場調査レポートは、正確な市場成長を予測するために、完全な競争環境と、定性的および定量的調査を用いた詳細なベンダー選定方法と分析を提供します。

ページTOPに戻る

目次

• 1 Executive Summary
o 1.1 Market overview
o Exhibit 01: Executive Summary - Chart on Market Overview
o Exhibit 02: Executive Summary - Data Table on Market Overview
o Exhibit 03: Executive Summary - Chart on Global Market Characteristics
o Exhibit 04: Executive Summary - Chart on Market By Geographical Landscape
o Exhibit 05: Executive Summary - Chart on Market Segmentation by Type
o Exhibit 06: Executive Summary - Chart on Market Segmentation by Therapy
o Exhibit 07: Executive Summary - Chart on Incremental Growth
o Exhibit 08: Executive Summary - Data Table on Incremental Growth
o Exhibit 09: Executive Summary - Chart on Vendor Market Positioning
• 2 Market Landscape
o 2.1 Market ecosystem
o Exhibit 10: Parent market
o Exhibit 11: Market Characteristics
• 3 Market Sizing
o 3.1 Market definition
o Exhibit 12: Offerings of vendors included in the market definition
o 3.2 Market segment analysis
o Exhibit 13: Market segments
o 3.3 Market size 2022
o 3.4 Market outlook: Forecast for 2022-2027
o Exhibit 14: Chart on Global - Market size and forecast 2022-2027 ($ million)
o Exhibit 15: Data Table on Global - Market size and forecast 2022-2027 ($ million)
o Exhibit 16: Chart on Global Market: Year-over-year growth 2022-2027 (%)
o Exhibit 17: Data Table on Global Market: Year-over-year growth 2022-2027 (%)
• 4 Historic Market Size
o 4.1 Global peripheral neuropathy treatment market 2017 - 2021
o Exhibit 18: Historic Market Size - Data Table on Global peripheral neuropathy treatment market 2017 - 2021 ($ million)
o 4.2 Type Segment Analysis 2017 - 2021
o Exhibit 19: Historic Market Size - Type Segment 2017 - 2021 ($ million)
o 4.3 Treatment Segment Analysis 2017 - 2021
o Exhibit 20: Historic Market Size - Treatment Segment 2017 - 2021 ($ million)
o 4.4 Geography Segment Analysis 2017 - 2021
o Exhibit 21: Historic Market Size - Geography Segment 2017 - 2021 ($ million)
o 4.5 Country Segment Analysis 2017 - 2021
o Exhibit 22: Historic Market Size - Country Segment 2017 - 2021 ($ million)
• 5 Five Forces Analysis
o 5.1 Five forces summary
o Exhibit 23: Five forces analysis - Comparison between 2022 and 2027
o 5.2 Bargaining power of buyers
o Exhibit 24: Chart on Bargaining power of buyers - Impact of key factors 2022 and 2027
o 5.3 Bargaining power of suppliers
o Exhibit 25: Bargaining power of suppliers - Impact of key factors in 2022 and 2027
o 5.4 Threat of new entrants
o Exhibit 26: Threat of new entrants - Impact of key factors in 2022 and 2027
o 5.5 Threat of substitutes
o Exhibit 27: Threat of substitutes - Impact of key factors in 2022 and 2027
o 5.6 Threat of rivalry
o Exhibit 28: Threat of rivalry - Impact of key factors in 2022 and 2027
o 5.7 Market condition
o Exhibit 29: Chart on Market condition - Five forces 2022 and 2027
• 6 Market Segmentation by Type
o 6.1 Market segments
o Exhibit 30: Chart on Type - Market share 2022-2027 (%)
o Exhibit 31: Data Table on Type - Market share 2022-2027 (%)
o 6.2 Comparison by Type
o Exhibit 32: Chart on Comparison by Type
o Exhibit 33: Data Table on Comparison by Type
o 6.3 Diabetic peripheral neuropathy - Market size and forecast 2022-2027
o Exhibit 34: Chart on Diabetic peripheral neuropathy - Market size and forecast 2022-2027 ($ million)
o Exhibit 35: Data Table on Diabetic peripheral neuropathy - Market size and forecast 2022-2027 ($ million)
o Exhibit 36: Chart on Diabetic peripheral neuropathy - Year-over-year growth 2022-2027 (%)
o Exhibit 37: Data Table on Diabetic peripheral neuropathy - Year-over-year growth 2022-2027 (%)
o 6.4 Chemotherapy induced peripheral neuropathy - Market size and forecast 2022-2027
o Exhibit 38: Chart on Chemotherapy induced peripheral neuropathy - Market size and forecast 2022-2027 ($ million)
o Exhibit 39: Data Table on Chemotherapy induced peripheral neuropathy - Market size and forecast 2022-2027 ($ million)
o Exhibit 40: Chart on Chemotherapy induced peripheral neuropathy - Year-over-year growth 2022-2027 (%)
o Exhibit 41: Data Table on Chemotherapy induced peripheral neuropathy - Year-over-year growth 2022-2027 (%)
o 6.5 Others - Market size and forecast 2022-2027
o Exhibit 42: Chart on Others - Market size and forecast 2022-2027 ($ million)
o Exhibit 43: Data Table on Others - Market size and forecast 2022-2027 ($ million)
o Exhibit 44: Chart on Others - Year-over-year growth 2022-2027 (%)
o Exhibit 45: Data Table on Others - Year-over-year growth 2022-2027 (%)
o 6.6 Market opportunity by Type
o Exhibit 46: Market opportunity by Type ($ million)
• 7 Market Segmentation by Therapy
o 7.1 Market segments
o Exhibit 47: Chart on Therapy - Market share 2022-2027 (%)
o Exhibit 48: Data Table on Therapy - Market share 2022-2027 (%)
o 7.2 Comparison by Therapy
o Exhibit 49: Chart on Comparison by Therapy
o Exhibit 50: Data Table on Comparison by Therapy
o 7.3 Pharmacological therapies - Market size and forecast 2022-2027
o Exhibit 51: Chart on Pharmacological therapies - Market size and forecast 2022-2027 ($ million)
o Exhibit 52: Data Table on Pharmacological therapies - Market size and forecast 2022-2027 ($ million)
o Exhibit 53: Chart on Pharmacological therapies - Year-over-year growth 2022-2027 (%)
o Exhibit 54: Data Table on Pharmacological therapies - Year-over-year growth 2022-2027 (%)
o 7.4 Non pharmacological therapies - Market size and forecast 2022-2027
o Exhibit 55: Chart on Non pharmacological therapies - Market size and forecast 2022-2027 ($ million)
o Exhibit 56: Data Table on Non pharmacological therapies - Market size and forecast 2022-2027 ($ million)
o Exhibit 57: Chart on Non pharmacological therapies - Year-over-year growth 2022-2027 (%)
o Exhibit 58: Data Table on Non pharmacological therapies - Year-over-year growth 2022-2027 (%)
o 7.5 Market opportunity by Therapy
o Exhibit 59: Market opportunity by Therapy ($ million)
• 8 Customer Landscape
o 8.1 Customer landscape overview
o Exhibit 60: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
• 9 Geographic Landscape
o 9.1 Geographic segmentation
o Exhibit 61: Chart on Market share By Geographical Landscape 2022-2027 (%)
o Exhibit 62: Data Table on Market share By Geographical Landscape 2022-2027 (%)
o 9.2 Geographic comparison
o Exhibit 63: Chart on Geographic comparison
o Exhibit 64: Data Table on Geographic comparison
o 9.3 North America - Market size and forecast 2022-2027
o Exhibit 65: Chart on North America - Market size and forecast 2022-2027 ($ million)
o Exhibit 66: Data Table on North America - Market size and forecast 2022-2027 ($ million)
o Exhibit 67: Chart on North America - Year-over-year growth 2022-2027 (%)
o Exhibit 68: Data Table on North America - Year-over-year growth 2022-2027 (%)
o 9.4 Europe - Market size and forecast 2022-2027
o Exhibit 69: Chart on Europe - Market size and forecast 2022-2027 ($ million)
o Exhibit 70: Data Table on Europe - Market size and forecast 2022-2027 ($ million)
o Exhibit 71: Chart on Europe - Year-over-year growth 2022-2027 (%)
o Exhibit 72: Data Table on Europe - Year-over-year growth 2022-2027 (%)
o 9.5 Asia - Market size and forecast 2022-2027
o Exhibit 73: Chart on Asia - Market size and forecast 2022-2027 ($ million)
o Exhibit 74: Data Table on Asia - Market size and forecast 2022-2027 ($ million)
o Exhibit 75: Chart on Asia - Year-over-year growth 2022-2027 (%)
o Exhibit 76: Data Table on Asia - Year-over-year growth 2022-2027 (%)
o 9.6 Rest of World (ROW) - Market size and forecast 2022-2027
o Exhibit 77: Chart on Rest of World (ROW) - Market size and forecast 2022-2027 ($ million)
o Exhibit 78: Data Table on Rest of World (ROW) - Market size and forecast 2022-2027 ($ million)
o Exhibit 79: Chart on Rest of World (ROW) - Year-over-year growth 2022-2027 (%)
o Exhibit 80: Data Table on Rest of World (ROW) - Year-over-year growth 2022-2027 (%)
o 9.7 US - Market size and forecast 2022-2027
o Exhibit 81: Chart on US - Market size and forecast 2022-2027 ($ million)
o Exhibit 82: Data Table on US - Market size and forecast 2022-2027 ($ million)
o Exhibit 83: Chart on US - Year-over-year growth 2022-2027 (%)
o Exhibit 84: Data Table on US - Year-over-year growth 2022-2027 (%)
o 9.8 Germany - Market size and forecast 2022-2027
o Exhibit 85: Chart on Germany - Market size and forecast 2022-2027 ($ million)
o Exhibit 86: Data Table on Germany - Market size and forecast 2022-2027 ($ million)
o Exhibit 87: Chart on Germany - Year-over-year growth 2022-2027 (%)
o Exhibit 88: Data Table on Germany - Year-over-year growth 2022-2027 (%)
o 9.9 China - Market size and forecast 2022-2027
o Exhibit 89: Chart on China - Market size and forecast 2022-2027 ($ million)
o Exhibit 90: Data Table on China - Market size and forecast 2022-2027 ($ million)
o Exhibit 91: Chart on China - Year-over-year growth 2022-2027 (%)
o Exhibit 92: Data Table on China - Year-over-year growth 2022-2027 (%)
o 9.10 UK - Market size and forecast 2022-2027
o Exhibit 93: Chart on UK - Market size and forecast 2022-2027 ($ million)
o Exhibit 94: Data Table on UK - Market size and forecast 2022-2027 ($ million)
o Exhibit 95: Chart on UK - Year-over-year growth 2022-2027 (%)
o Exhibit 96: Data Table on UK - Year-over-year growth 2022-2027 (%)
o 9.11 Japan - Market size and forecast 2022-2027
o Exhibit 97: Chart on Japan - Market size and forecast 2022-2027 ($ million)
o Exhibit 98: Data Table on Japan - Market size and forecast 2022-2027 ($ million)
o Exhibit 99: Chart on Japan - Year-over-year growth 2022-2027 (%)
o Exhibit 100: Data Table on Japan - Year-over-year growth 2022-2027 (%)
o 9.12 Market opportunity By Geographical Landscape
o Exhibit 101: Market opportunity By Geographical Landscape ($ million)
• 10 Drivers, Challenges, and Trends
o 10.1 Market drivers
o 10.2 Market challenges
o 10.3 Impact of drivers and challenges
o Exhibit 102: Impact of drivers and challenges in 2022 and 2027
o 10.4 Market trends
• 11 Vendor Landscape
o 11.1 Overview
o 11.2 Vendor landscape
o Exhibit 103: Overview on Criticality of inputs and Factors of differentiation
o 11.3 Landscape disruption
o Exhibit 104: Overview on factors of disruption
o 11.4 Industry risks
o Exhibit 105: Impact of key risks on business
• 12 Vendor Analysis
o 12.1 Vendors covered
o Exhibit 106: Vendors covered
o 12.2 Market positioning of vendors
o Exhibit 107: Matrix on vendor position and classification
o 12.3 Apotex Inc.
o Exhibit 108: Apotex Inc. - Overview
o Exhibit 109: Apotex Inc. - Product / Service
o Exhibit 110: Apotex Inc. - Key offerings
o 12.4 Assertio Therapeutics Inc.
o Exhibit 111: Assertio Therapeutics Inc. - Overview
o Exhibit 112: Assertio Therapeutics Inc. - Product / Service
o Exhibit 113: Assertio Therapeutics Inc. - Key offerings
o 12.5 AstraZeneca Plc
o Exhibit 114: AstraZeneca Plc - Overview
o Exhibit 115: AstraZeneca Plc - Product / Service
o Exhibit 116: AstraZeneca Plc - Key news
o Exhibit 117: AstraZeneca Plc - Key offerings
o 12.6 Cadila Pharmaceuticals Ltd.
o Exhibit 118: Cadila Pharmaceuticals Ltd. - Overview
o Exhibit 119: Cadila Pharmaceuticals Ltd. - Product / Service
o Exhibit 120: Cadila Pharmaceuticals Ltd. - Key offerings
o 12.7 Cipla Ltd.
o Exhibit 121: Cipla Ltd. - Overview
o Exhibit 122: Cipla Ltd. - Business segments
o Exhibit 123: Cipla Ltd. - Key news
o Exhibit 124: Cipla Ltd. - Key offerings
o Exhibit 125: Cipla Ltd. - Segment focus
o 12.8 Daiichi Sankyo Co. Ltd.
o Exhibit 126: Daiichi Sankyo Co. Ltd. - Overview
o Exhibit 127: Daiichi Sankyo Co. Ltd. - Business segments
o Exhibit 128: Daiichi Sankyo Co. Ltd. - Key news
o Exhibit 129: Daiichi Sankyo Co. Ltd. - Key offerings
o Exhibit 130: Daiichi Sankyo Co. Ltd. - Segment focus
o 12.9 Dr Reddys Laboratories Ltd.
o Exhibit 131: Dr Reddys Laboratories Ltd. - Overview
o Exhibit 132: Dr Reddys Laboratories Ltd. - Business segments
o Exhibit 133: Dr Reddys Laboratories Ltd. - Key offerings
o Exhibit 134: Dr Reddys Laboratories Ltd. - Segment focus
o 12.10 Eli Lilly and Co.
o Exhibit 135: Eli Lilly and Co. - Overview
o Exhibit 136: Eli Lilly and Co. - Product / Service
o Exhibit 137: Eli Lilly and Co. - Key offerings
o 12.11 Endo International Plc
o Exhibit 138: Endo International Plc - Overview
o Exhibit 139: Endo International Plc - Business segments
o Exhibit 140: Endo International Plc - Key news
o Exhibit 141: Endo International Plc - Key offerings
o Exhibit 142: Endo International Plc - Segment focus
o 12.12 Hikma Pharmaceuticals Plc
o Exhibit 143: Hikma Pharmaceuticals Plc - Overview
o Exhibit 144: Hikma Pharmaceuticals Plc - Business segments
o Exhibit 145: Hikma Pharmaceuticals Plc - Key offerings
o Exhibit 146: Hikma Pharmaceuticals Plc - Segment focus
o 12.13 Johnson and Johnson
o Exhibit 147: Johnson and Johnson - Overview
o Exhibit 148: Johnson and Johnson - Business segments
o Exhibit 149: Johnson and Johnson - Key news
o Exhibit 150: Johnson and Johnson - Key offerings
o Exhibit 151: Johnson and Johnson - Segment focus
o 12.14 Lupin Ltd.
o Exhibit 152: Lupin Ltd. - Overview
o Exhibit 153: Lupin Ltd. - Product / Service
o Exhibit 154: Lupin Ltd. - Key news
o Exhibit 155: Lupin Ltd. - Key offerings
o 12.15 Novartis AG
o Exhibit 156: Novartis AG - Overview
o Exhibit 157: Novartis AG - Business segments
o Exhibit 158: Novartis AG - Key offerings
o Exhibit 159: Novartis AG - Segment focus
o 12.16 Pfizer Inc.
o Exhibit 160: Pfizer Inc. - Overview
o Exhibit 161: Pfizer Inc. - Product / Service
o Exhibit 162: Pfizer Inc. - Key news
o Exhibit 163: Pfizer Inc. - Key offerings
o 12.17 Viatris Inc.
o Exhibit 164: Viatris Inc. - Overview
o Exhibit 165: Viatris Inc. - Business segments
o Exhibit 166: Viatris Inc. - Key offerings
o Exhibit 167: Viatris Inc. - Segment focus
• 13 Appendix
o 13.1 Scope of the report
o 13.2 Inclusions and exclusions checklist
o Exhibit 168: Inclusions checklist
o Exhibit 169: Exclusions checklist
o 13.3 Currency conversion rates for US$
o Exhibit 170: Currency conversion rates for US$
o 13.4 Research methodology
o Exhibit 171: Research methodology
o Exhibit 172: Validation techniques employed for market sizing
o Exhibit 173: Information sources
o 13.5 List of abbreviations
o Exhibit 174: List of abbreviations


Exhibits:
Exhibits1: Executive Summary - Chart on Market Overview
Exhibits2: Executive Summary - Data Table on Market Overview
Exhibits3: Executive Summary - Chart on Global Market Characteristics
Exhibits4: Executive Summary - Chart on Market By Geographical Landscape
Exhibits5: Executive Summary - Chart on Market Segmentation by Type
Exhibits6: Executive Summary - Chart on Market Segmentation by Therapy
Exhibits7: Executive Summary - Chart on Incremental Growth
Exhibits8: Executive Summary - Data Table on Incremental Growth
Exhibits9: Executive Summary - Chart on Vendor Market Positioning
Exhibits10: Parent market
Exhibits11: Market Characteristics
Exhibits12: Offerings of vendors included in the market definition
Exhibits13: Market segments
Exhibits14: Chart on Global - Market size and forecast 2022-2027 ($ million)
Exhibits15: Data Table on Global - Market size and forecast 2022-2027 ($ million)
Exhibits16: Chart on Global Market: Year-over-year growth 2022-2027 (%)
Exhibits17: Data Table on Global Market: Year-over-year growth 2022-2027 (%)
Exhibits18: Historic Market Size - Data Table on Global peripheral neuropathy treatment market 2017 - 2021 ($ million)
Exhibits19: Historic Market Size - Type Segment 2017 - 2021 ($ million)
Exhibits20: Historic Market Size - Treatment Segment 2017 - 2021 ($ million)
Exhibits21: Historic Market Size - Geography Segment 2017 - 2021 ($ million)
Exhibits22: Historic Market Size - Country Segment 2017 - 2021 ($ million)
Exhibits23: Five forces analysis - Comparison between 2022 and 2027
Exhibits24: Chart on Bargaining power of buyers - Impact of key factors 2022 and 2027
Exhibits25: Bargaining power of suppliers - Impact of key factors in 2022 and 2027
Exhibits26: Threat of new entrants - Impact of key factors in 2022 and 2027
Exhibits27: Threat of substitutes - Impact of key factors in 2022 and 2027
Exhibits28: Threat of rivalry - Impact of key factors in 2022 and 2027
Exhibits29: Chart on Market condition - Five forces 2022 and 2027
Exhibits30: Chart on Type - Market share 2022-2027 (%)
Exhibits31: Data Table on Type - Market share 2022-2027 (%)
Exhibits32: Chart on Comparison by Type
Exhibits33: Data Table on Comparison by Type
Exhibits34: Chart on Diabetic peripheral neuropathy - Market size and forecast 2022-2027 ($ million)
Exhibits35: Data Table on Diabetic peripheral neuropathy - Market size and forecast 2022-2027 ($ million)
Exhibits36: Chart on Diabetic peripheral neuropathy - Year-over-year growth 2022-2027 (%)
Exhibits37: Data Table on Diabetic peripheral neuropathy - Year-over-year growth 2022-2027 (%)
Exhibits38: Chart on Chemotherapy induced peripheral neuropathy - Market size and forecast 2022-2027 ($ million)
Exhibits39: Data Table on Chemotherapy induced peripheral neuropathy - Market size and forecast 2022-2027 ($ million)
Exhibits40: Chart on Chemotherapy induced peripheral neuropathy - Year-over-year growth 2022-2027 (%)
Exhibits41: Data Table on Chemotherapy induced peripheral neuropathy - Year-over-year growth 2022-2027 (%)
Exhibits42: Chart on Others - Market size and forecast 2022-2027 ($ million)
Exhibits43: Data Table on Others - Market size and forecast 2022-2027 ($ million)
Exhibits44: Chart on Others - Year-over-year growth 2022-2027 (%)
Exhibits45: Data Table on Others - Year-over-year growth 2022-2027 (%)
Exhibits46: Market opportunity by Type ($ million)
Exhibits47: Chart on Therapy - Market share 2022-2027 (%)
Exhibits48: Data Table on Therapy - Market share 2022-2027 (%)
Exhibits49: Chart on Comparison by Therapy
Exhibits50: Data Table on Comparison by Therapy
Exhibits51: Chart on Pharmacological therapies - Market size and forecast 2022-2027 ($ million)
Exhibits52: Data Table on Pharmacological therapies - Market size and forecast 2022-2027 ($ million)
Exhibits53: Chart on Pharmacological therapies - Year-over-year growth 2022-2027 (%)
Exhibits54: Data Table on Pharmacological therapies - Year-over-year growth 2022-2027 (%)
Exhibits55: Chart on Non pharmacological therapies - Market size and forecast 2022-2027 ($ million)
Exhibits56: Data Table on Non pharmacological therapies - Market size and forecast 2022-2027 ($ million)
Exhibits57: Chart on Non pharmacological therapies - Year-over-year growth 2022-2027 (%)
Exhibits58: Data Table on Non pharmacological therapies - Year-over-year growth 2022-2027 (%)
Exhibits59: Market opportunity by Therapy ($ million)
Exhibits60: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
Exhibits61: Chart on Market share By Geographical Landscape 2022-2027 (%)
Exhibits62: Data Table on Market share By Geographical Landscape 2022-2027 (%)
Exhibits63: Chart on Geographic comparison
Exhibits64: Data Table on Geographic comparison
Exhibits65: Chart on North America - Market size and forecast 2022-2027 ($ million)
Exhibits66: Data Table on North America - Market size and forecast 2022-2027 ($ million)
Exhibits67: Chart on North America - Year-over-year growth 2022-2027 (%)
Exhibits68: Data Table on North America - Year-over-year growth 2022-2027 (%)
Exhibits69: Chart on Europe - Market size and forecast 2022-2027 ($ million)
Exhibits70: Data Table on Europe - Market size and forecast 2022-2027 ($ million)
Exhibits71: Chart on Europe - Year-over-year growth 2022-2027 (%)
Exhibits72: Data Table on Europe - Year-over-year growth 2022-2027 (%)
Exhibits73: Chart on Asia - Market size and forecast 2022-2027 ($ million)
Exhibits74: Data Table on Asia - Market size and forecast 2022-2027 ($ million)
Exhibits75: Chart on Asia - Year-over-year growth 2022-2027 (%)
Exhibits76: Data Table on Asia - Year-over-year growth 2022-2027 (%)
Exhibits77: Chart on Rest of World (ROW) - Market size and forecast 2022-2027 ($ million)
Exhibits78: Data Table on Rest of World (ROW) - Market size and forecast 2022-2027 ($ million)
Exhibits79: Chart on Rest of World (ROW) - Year-over-year growth 2022-2027 (%)
Exhibits80: Data Table on Rest of World (ROW) - Year-over-year growth 2022-2027 (%)
Exhibits81: Chart on US - Market size and forecast 2022-2027 ($ million)
Exhibits82: Data Table on US - Market size and forecast 2022-2027 ($ million)
Exhibits83: Chart on US - Year-over-year growth 2022-2027 (%)
Exhibits84: Data Table on US - Year-over-year growth 2022-2027 (%)
Exhibits85: Chart on Germany - Market size and forecast 2022-2027 ($ million)
Exhibits86: Data Table on Germany - Market size and forecast 2022-2027 ($ million)
Exhibits87: Chart on Germany - Year-over-year growth 2022-2027 (%)
Exhibits88: Data Table on Germany - Year-over-year growth 2022-2027 (%)
Exhibits89: Chart on China - Market size and forecast 2022-2027 ($ million)
Exhibits90: Data Table on China - Market size and forecast 2022-2027 ($ million)
Exhibits91: Chart on China - Year-over-year growth 2022-2027 (%)
Exhibits92: Data Table on China - Year-over-year growth 2022-2027 (%)
Exhibits93: Chart on UK - Market size and forecast 2022-2027 ($ million)
Exhibits94: Data Table on UK - Market size and forecast 2022-2027 ($ million)
Exhibits95: Chart on UK - Year-over-year growth 2022-2027 (%)
Exhibits96: Data Table on UK - Year-over-year growth 2022-2027 (%)
Exhibits97: Chart on Japan - Market size and forecast 2022-2027 ($ million)
Exhibits98: Data Table on Japan - Market size and forecast 2022-2027 ($ million)
Exhibits99: Chart on Japan - Year-over-year growth 2022-2027 (%)
Exhibits100: Data Table on Japan - Year-over-year growth 2022-2027 (%)
Exhibits101: Market opportunity By Geographical Landscape ($ million)
Exhibits102: Impact of drivers and challenges in 2022 and 2027
Exhibits103: Overview on Criticality of inputs and Factors of differentiation
Exhibits104: Overview on factors of disruption
Exhibits105: Impact of key risks on business
Exhibits106: Vendors covered
Exhibits107: Matrix on vendor position and classification
Exhibits108: Apotex Inc. - Overview
Exhibits109: Apotex Inc. - Product / Service
Exhibits110: Apotex Inc. - Key offerings
Exhibits111: Assertio Therapeutics Inc. - Overview
Exhibits112: Assertio Therapeutics Inc. - Product / Service
Exhibits113: Assertio Therapeutics Inc. - Key offerings
Exhibits114: AstraZeneca Plc - Overview
Exhibits115: AstraZeneca Plc - Product / Service
Exhibits116: AstraZeneca Plc - Key news
Exhibits117: AstraZeneca Plc - Key offerings
Exhibits118: Cadila Pharmaceuticals Ltd. - Overview
Exhibits119: Cadila Pharmaceuticals Ltd. - Product / Service
Exhibits120: Cadila Pharmaceuticals Ltd. - Key offerings
Exhibits121: Cipla Ltd. - Overview
Exhibits122: Cipla Ltd. - Business segments
Exhibits123: Cipla Ltd. - Key news
Exhibits124: Cipla Ltd. - Key offerings
Exhibits125: Cipla Ltd. - Segment focus
Exhibits126: Daiichi Sankyo Co. Ltd. - Overview
Exhibits127: Daiichi Sankyo Co. Ltd. - Business segments
Exhibits128: Daiichi Sankyo Co. Ltd. - Key news
Exhibits129: Daiichi Sankyo Co. Ltd. - Key offerings
Exhibits130: Daiichi Sankyo Co. Ltd. - Segment focus
Exhibits131: Dr Reddys Laboratories Ltd. - Overview
Exhibits132: Dr Reddys Laboratories Ltd. - Business segments
Exhibits133: Dr Reddys Laboratories Ltd. - Key offerings
Exhibits134: Dr Reddys Laboratories Ltd. - Segment focus
Exhibits135: Eli Lilly and Co. - Overview
Exhibits136: Eli Lilly and Co. - Product / Service
Exhibits137: Eli Lilly and Co. - Key offerings
Exhibits138: Endo International Plc - Overview
Exhibits139: Endo International Plc - Business segments
Exhibits140: Endo International Plc - Key news
Exhibits141: Endo International Plc - Key offerings
Exhibits142: Endo International Plc - Segment focus
Exhibits143: Hikma Pharmaceuticals Plc - Overview
Exhibits144: Hikma Pharmaceuticals Plc - Business segments
Exhibits145: Hikma Pharmaceuticals Plc - Key offerings
Exhibits146: Hikma Pharmaceuticals Plc - Segment focus
Exhibits147: Johnson and Johnson - Overview
Exhibits148: Johnson and Johnson - Business segments
Exhibits149: Johnson and Johnson - Key news
Exhibits150: Johnson and Johnson - Key offerings
Exhibits151: Johnson and Johnson - Segment focus
Exhibits152: Lupin Ltd. - Overview
Exhibits153: Lupin Ltd. - Product / Service
Exhibits154: Lupin Ltd. - Key news
Exhibits155: Lupin Ltd. - Key offerings
Exhibits156: Novartis AG - Overview
Exhibits157: Novartis AG - Business segments
Exhibits158: Novartis AG - Key offerings
Exhibits159: Novartis AG - Segment focus
Exhibits160: Pfizer Inc. - Overview
Exhibits161: Pfizer Inc. - Product / Service
Exhibits162: Pfizer Inc. - Key news
Exhibits163: Pfizer Inc. - Key offerings
Exhibits164: Viatris Inc. - Overview
Exhibits165: Viatris Inc. - Business segments
Exhibits166: Viatris Inc. - Key offerings
Exhibits167: Viatris Inc. - Segment focus
Exhibits168: Inclusions checklist
Exhibits169: Exclusions checklist
Exhibits170: Currency conversion rates for US$
Exhibits171: Research methodology
Exhibits172: Validation techniques employed for market sizing
Exhibits173: Information sources
Exhibits174: List of abbreviations